Active immunotherapy of multiple myeloma

Houet, Leonora; Veelken, Hendrik

doi:10.1016/j.ejca.2006.03.008

Cited by 21 publications

(22 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, several putative Ags in myeloma cells can serve as such targets. These include MUC-1 and cancer-testis Ags such as MAGE and NY-ESO-1 (52). Which of these Ags may be targeted by myeloma cell-DC vaccines remains to be determined.…”

Section: Discussionmentioning

confidence: 99%

Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma

Cohen

Haimovich

Hollander

2009

The Journal of Immunology

View full text Add to dashboard Cite

Multiple myeloma is an incurable plasma cell malignancy. Immunotherapy in myeloma patients had limited success to date. We have previously demonstrated that dendritic cells (DCs) pulsed with autologous Ig Id induced Id-reactive CD8+ T cells and protection against a myeloma tumor challenge. In this work, we studied the therapeutic efficacy of chemotherapy combined with different formulations of DC-based vaccines in mice bearing large plasma cell tumors. The comparative study demonstrated that s.c. injection of DCs loaded with Id coupled to keyhole limpet hemocyanin, s.c. injection of DCs loaded with irradiated tumor cells, and intratumoral injection of naive DCs were similarly effective in mediating tumor regression and long-term survival. However, whereas the Id-keyhole limpet hemocyanin-DC vaccine was inefficient against myeloma cells that lost expression of the Ig H chain, intratumoral injection of naive DCs and s.c. injection of DCs loaded with irradiated tumor cells were highly effective against cells producing L chains only. This may be of particular importance for patients with L chain myeloma. Given that T cells respond primarily to peptides derived from H chain CDRs, attempts to treat L chain disease with myeloma protein-pulsed DCs may be futile. Vaccination with tumor cell-loaded DCs may, however, induce an effective antitumor response.

show abstract

Section: Discussionmentioning

confidence: 99%

Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma

Cohen

Haimovich

Hollander

2009

The Journal of Immunology

View full text Add to dashboard Cite

show abstract

“…The Id is expressed and presented in an HLA-restricted manner on the surface of malignant plasma cells [3]. The secreted idiotype was up taken and presented by dendritic cells and may act as T cell antigens [6]. However, idiotype vaccines were weakly immunogenic and failed to elicit a measurable clinical benefit even when combined with strong adjuvants such as granulocyte-monocyte colonystimulating factor (GM-CSF), IL-12, alum or keyhole limpet hemocyanin [3].…”

Section: Idiotype Vaccinesmentioning

confidence: 99%

“…Idiotype-loaded DCs have been used as vaccines in MM patients, mostly in the setting of clinical remission after auto transplant [6]. Decreased regulatory-T cell function and minimal disease state post transplant suggest that this is an optimal setting for vaccination [5].…”

Section: Dc-based Vaccinesmentioning

confidence: 99%

“…Idiotype refers to the unique immunological properties of any individual immunoglobulin [6]. The Id is expressed and presented in an HLA-restricted manner on the surface of malignant plasma cells [3].…”

Section: Idiotype Vaccinesmentioning

confidence: 99%

“…The importance of host antitumor immunity is evidenced by long-term molecular CR observed post allogeneic stem cell transplantation [5] due to a graft-versus-myeloma effect exerted by donor-derived T lymphocytes [6]. An overdue era of immune therapy in MM has begun [7].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Encouraging Debut of Immunotherapy In Myeloma

Hamed¹

2016

CTOIJ

View full text Add to dashboard Cite

Current Awareness in Hematological Oncology

2007

Hematological Oncology

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of hematological oncology. Each bibliography is divided into 14 sections: 1 Reviews; 2 General; Leukemias: 3 Lymphoblastic; 4 Myeloid & Myelodysplastic Syndromes; 5 Chronic; 6 Others; Lymphomas: 7 Hodgkin's; 8 Non‐Hodgkin's; 9 Plasmacytomas/Multiple Myelomas; 10 Others; 11 Bone Marrow Transplantation; 12 Cytokines; 13 Diagnosis; 14 Cytogenetics. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Active immunotherapy of multiple myeloma

Cited by 21 publications

References 65 publications

Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma

Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma

Encouraging Debut of Immunotherapy In Myeloma

Current Awareness in Hematological Oncology

Contact Info

Product

Resources

About